Objectives: The unplanned readmission rate after carotid procedures is approximately 6%, but most prior studies are limited to only index hospital readmission. Up to one in three postoperative readmissions occur at a different hospital and are missed by current metrics. There are no national studies examining readmission after carotid endarterectomy and carotid artery stenting (CAS), including to different hospitals. The purpose of this study was to compare unplanned readmission incidence and risk factors between carotid endarterectomy and CAS, including readmissions to any hospital, in a nationally representative sample.
Objectives: Conclusions from landmark trials investigating medical versus surgical management of asymptomatic carotid occlusive disease may not be supported with the advancement of statin therapy for lipid management. We set out to evaluate the current understanding of the natural history of asymptomatic, severe internal carotid artery (ICA) stenosis through an analysis of our own results, which, in turn, will optimize our practice patterns and improve patient outcomes.
Methods: This single-institution, retrospective study identified all patients with severe ICA stenosis by North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria (end-diastolic velocity of either ICA $ 140 cm/s) applied to carotid duplexes performed from 2007 to 2017. Out 3071 individual bilateral carotid duplex studies from 1095 patients, 311 patients had duplexes that demonstrated severe ICA stenosis of 80% to 99%. Of these patients, 229 were asymptomatic at initial presentation. Over the study duration, we identified patients who developed neurologic symptoms attributed to carotid occlusive disease, progressed to ICA occlusion, or crossed over and underwent carotid endarterectomy (CEA), analyzing demographic variables, comorbidities, medications, smoking history, and perioperative outcomes.
Results: Of the 229 asymptomatic patients with severe ICA stenosis, 56 patients were strictly medically managed. Nine (16%) developed neurologic symptoms and underwent CEA. Of the 173 surgically managed patients, 5 (2.9%) developed nonfatal periprocedural stroke, another 5 (2.9%) developed focal neurologic symptoms beyond thirty days after undergoing CEA, and 6 (3.5%) sustained non-neurologic perioperative complications (cranial nerve injury or hematoma). No mortalities occurred as a result of either treatment. The mean follow-up was 2.99 years. When comparing characteristics of both cohorts and those who developed neurologic symptoms, there were no differences in demographics, comorbidities, or medications. The majority of patients who crossed over to surgical treatment did so within the first 2 years of surveillance (Fig) , with significantly earlier events compared with the surgical group (P ¼ .001). The number needed to treat to prevent stroke was 7.59 CEAs.
Conclusions: In our population, patients with asymptomatic, severe ICA stenosis may benefit from CEA compared with medical management that includes antiplatelet and statin therapy. For those medically managed patients, close surveillance with carotid duplex is recommended to salvage those who crossover and require CEA.
